CO010 | MAPPING HEMOSTATIC BIOMARKER EXPRESSION ACROSS CANCER TYPES AND STAGES WITHIN THE HYPERCAN COHORT
Abstract
Background and Aims. Systemic hypercoagulability is a recognized hallmark of malignancy. Growing evidence suggests that markers of hemostatic activation may serve as surrogates for tumor aggressiveness and prognosis, other than thrombosis; however, a comprehensive characterization of this "hemostatic signature" within an inflammatory milieu across large prospective cohorts remains limited. This study aims to evaluate tumor-specific procoagulant profiles within a large, prospective, multicenter cohort of patients diagnosed with common solid malignancies. Methods. We analyzed 4,292 patients from the HYPERCAN study (NCT02622815) with newly diagnosed non-small cell lung (NSCLC), gastric (GC), colorectal (CRC), and breast cancer (BC). Plasma samples were collected at diagnosis to assess thrombin generation (TG_CAT), D-dimer, fibrinogen, and prothrombin fragment 1+2 (F1+2). All participants provided informed consent, and data were analyzed using SPSS 21.0. Results. Metastatic disease was predominant in the NSCLC (67%), GC (53%), and CRC (47%) cohorts, whereas 75% of the BC cohort consisted of high-risk surgically resected patients. Fibrinogen levels were significantly elevated in metastatic cases compared with resected cases across all tumor types (p < 0.001), with the highest concentrations observed in metastatic NSCLC. Notably, CRC exhibited a stage-dependent, stepwise increase in fibrinogen (348 to 444 mg/dL; p < 0.05). While FVIII was consistently higher in metastatic groups (except GC), D-dimer peaks were most pronounced in metastatic GC and NSCLC (p < 0.002). Although F1+2 effectively differentiated metastatic from localized disease in NSCLC, GC, and BC (p < 0.05), it showed no discriminatory power in CRC. Finally, the highest TG-Peak and ETP values were found in BC and NSCLC; in the latter, TG values positively correlated with disease burden, significantly distinguishing metastatic from resected patients (p < 0.003). Conclusions. These data demonstrate that cancer-associated hypercoagulability is a heterogeneous, tumor-specific hallmark rather than a uniform systemic event. While fibrinogen and D-dimer remain robust indicators of metastatic progression—particularly in NSCLC and GC—the sensitivity of markers like F1+2 and TG varies by histotype. These findings underscore the necessity of tailored hemostatic profiling to better understand biological heterogeneity and improve risk stratification across diverse malignancies.
Related
- RNF152 promoter methylation and gene expression in oral premalignant lesions and oral squamous cell carcinoma: implications for epigenetic biomarker development
- Biomarker Convert: a novel approach to transform plasma pTau217 results across immunoassay and mass spectrometry analytical platforms
- Performance of protein panels is inflated across many biomarker studies
- Cross-species mapping of acute psychedelic-responsive genes links HTR2A cortical expression, cell-type enrichment, and human cortical expression modules.
- eNAMPT is a plasma biomarker of COVID-19 severity and ARDS progression linked to increased immune effector cell expression
BibTeX
@article{marchetti2026co010,
title = {{CO010 | MAPPING HEMOSTATIC BIOMARKER EXPRESSION ACROSS CANCER TYPES AND STAGES WITHIN THE HYPERCAN COHORT}},
author = {Marina Marchetti},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/712},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO010 | MAPPING HEMOSTATIC BIOMARKER EXPRESSION ACROSS CANCER TYPES AND STAGES WITHIN THE HYPERCAN COHORT
AU - Marina Marchetti
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/712
AB - Background and Aims. Systemic hypercoagulability is a recognized hallmark of malignancy. Growing evidence suggests that markers of hemostatic activation may serve as surrogates for tumor aggressiveness and prognosis, other than thrombosis; however, a comprehensive characterization of this "hemostatic signature" within an inflammatory milieu across large prospective cohorts remains limited. This study aims to evaluate tumor-specific procoagulant profiles within a large, prospective, multicenter cohort of patients diagnosed with common solid malignancies. Methods. We analyzed 4,292 patients from the HYPERCAN study (NCT02622815) with newly diagnosed non-small cell lung (NSCLC), gastric (GC), colorectal (CRC), and breast cancer (BC). Plasma samples were collected at diagnosis to assess thrombin generation (TG_CAT), D-dimer, fibrinogen, and prothrombin fragment 1+2 (F1+2). All participants provided informed consent, and data were analyzed using SPSS 21.0. Results. Metastatic disease was predominant in the NSCLC (67%), GC (53%), and CRC (47%) cohorts, whereas 75% of the BC cohort consisted of high-risk surgically resected patients. Fibrinogen levels were significantly elevated in metastatic cases compared with resected cases across all tumor types (p < 0.001), with the highest concentrations observed in metastatic NSCLC. Notably, CRC exhibited a stage-dependent, stepwise increase in fibrinogen (348 to 444 mg/dL; p < 0.05). While FVIII was consistently higher in metastatic groups (except GC), D-dimer peaks were most pronounced in metastatic GC and NSCLC (p < 0.002). Although F1+2 effectively differentiated metastatic from localized disease in NSCLC, GC, and BC (p < 0.05), it showed no discriminatory power in CRC. Finally, the highest TG-Peak and ETP values were found in BC and NSCLC; in the latter, TG values positively correlated with disease burden, significantly distinguishing metastatic from resected patients (p < 0.003). Conclusions. These data demonstrate that cancer-associated hypercoagulability is a heterogeneous, tumor-specific hallmark rather than a uniform systemic event. While fibrinogen and D-dimer remain robust indicators of metastatic progression—particularly in NSCLC and GC—the sensitivity of markers like F1+2 and TG varies by histotype. These findings underscore the necessity of tailored hemostatic profiling to better understand biological heterogeneity and improve risk stratification across diverse malignancies.
SN - 2785-5309
ER -